Recruiting

Peripheral Neuropathy

Sponsor:

Loma Linda University

Code:

NCT05577390

Conditions

Peripheral Neuropathy With Type 2 Diabetes

Eligibility Criteria

Sex: All

Age: 45 - 70+

Healthy Volunteers: Not accepted

Interventions

Intraneural Facilitation Therapy Treatment

Standard Physical Therapy Treatment

Study Details

Brief summary:

Diabetic peripheral neuropathy is one of the most common and costly microvascular complications of diabetes impacting more than 50% of patients and costing more than 10.1 billion dollars annually. Intraneural Facilitation Therapy (INF® Therapy) is a non-invasive technique that has shown to improve balance and pain in patients with Type 2 Diabetic Peripheral Neuropathy (T2DPN); however, the underlying physiological mechanisms need further understanding. The purpose of this study is to investigate the physiological mechanisms behind two approaches to treating T2DPN, INF® Therapy and standard physical therapy. Eligible subjects presenting with diabetic neuropathy symptoms will be recruited and referred to the Loma Linda University Health's Neuropathic Therapy Center. Forty patients will be evenly randomized into two groups: an INF® Therapy Treatment group and standard physical therapy treatment group. Subjects will participate in 11 study visits over a period of 6 weeks. Non-invasive assessments will measure neuropathy pain, heart rate variability, neuropathy severity, blood oxygen levels, and blood flow under the skin. Lab draws will measure inflammation levels in the blood and how well blood sugar levels have been maintained over a period of about 3 months. Descriptive statistics and repeated measures ANOVA will be used to analyze data and answer the research questions. The findings of this study will provide a better understanding of how INF® Therapy and standard physical therapy work, subsequently improving non-invasive treatment methods for T2DPN patients.

Conditions

Peripheral Neuropathy With Type 2 Diabetes

Study ID

NCT05577390

Start date

Jan 8, 2024

Status verified date

Nov, 2025

Completion date

Aug 1, 2027

Anticipated

Primary completion date

Aug 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 45 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Between the ages of 45 and 85
  • Moderate to severe type II diabetic neuropathy with one or more symptoms including: numbness, tingling, burning, sharp pain, and/or increased sensitivity.
  • Diagnosis confirmed by a physician.
  • Cellphone access with Android 5.0 and up or iOS 14.0 or later.

Exclusion Criteria:

Subjects with a medical condition predisposing them to medical decline during the next 6 months will be excluded from the study. Examples include:

  • Chemotherapy
  • Radiation
  • Lower extremity amputations
  • Open wounds
  • Documented active drug and or alcohol misuse
  • Chronic liver disease
  • Active inflammations
  • Other types of neuropathies not associated with diabetes including B12 deficiency and Charcot Marie Tooth
  • Morbid obesity
  • Pregnancy.
  • Taking beta blockers
  • Unable to maintain steady fingers or operate a cellphone
  • Smoking or ingesting marijuana
  • Having a pacemaker
  • Allergies to cobalt, chrome, or nickel

Study Design

Enrollment

40 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Intraneural Facilitation Therapy Treatment Group

Subjects will receive nine 60-minute INF® Therapy Treatments during sessions 2 through 10. INF® Therapy is a non-invasive treatment that helps eliminate pain, tingling, numbness, and other symptoms that come with neuropathy.

experimental: Standard Physical Therapy Treatment Group

Subjects will receive nine 60-minute standard physical therapy treatments during sessions 2 through 10.

Interventions

Intraneural Facilitation Therapy Treatment

Intraneural Facilitation Therapy uses three manual holds to bias blood flow to closed endoneurial capillaries. The first is the facilitation hold, which is thought to pressurize the nervous system and bias circulation from the artery into the epineurium. This hold stretches the nerve further than the artery, increasing the amount of elastin in the artery and enlarging the opening of the arterial junction increasing blood into the epineurium. The secondary hold then increases epineurial blood into the transperineurial vessels increasing pressure into the endoneurial capillaries of the site being treated. The third hold, known as the sub hold, encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of Bernoulli's principle. The series of stretches will be repeated on the affected side for the treatment duration.

Standard Physical Therapy Treatment

The standard physical therapy treatment includes muscle stretching, balance, and strengthening exercises known to improve neuropathy symptoms.

Primary outcome measure

  • The Impact of INF® Therapy and Standard Physical Therapy on Heart Rate Variability [ Time Frame: Through study completion, an average of 6 weeks. ]

Central Contacts and Locations

Central contacts

Mark Bussell, DPT, OCS

909-558-6799ntcresearch@llu.edu

Locations

Loma Linda University Health Neuropathic Therapy Center

Recruiting

Loma Linda, California, United States, 92350

Contacts

Mark Bussell, DPT, OCS

909-558-6799ntcresearch@llu.edu

Principal Investigator:

Mark Bussell, DPT, OCS

More Information

Sponsor

Loma Linda University

Last update posted

Nov 19, 2025

Last verified

Nov, 2025

Keywords

  • Intraneural Facilitation Therapy
  • Type 2 Diabetes
  • Neuropathy
  • Heart rate variability

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Loma Linda University on 2025-11-19.